Latest From REGiMMUNE Corp.
In many ways, Mebiopharm's investment experience is illustrative of the challenges facing the bioventure sector as a whole in Japan, or indeed anywhere else. The need to secure sufficient funding and maintain momentum for lead pipeline projects will no doubt sound familiar to the management of any startup looking to commercialize new technology.
Astellas has signed an agreement with the Japanese bioventure REGiMMUNE to develop platform technology for the development and delivery of vaccines.
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Pacific Rim
- Parent & Subsidiaries
- REGiMMUNE Corp.
- Senior Management
Haru Morita, Pres. & CEO
Reiko Namikawa, MD, PhD, SVP, Dev. & Strategy
Teikichi Aoyagi, PhD, SVP, Chief Dev. Officer
- Contact Info
Phone: (81) 3 3456 0820
Tokyo Industry Trade Ctr. 607
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.